Dubrovnik, 9 June 2016 – During the next two days, the key pharmaceutical industry leaders from the generic, biosimilar and value added medicines industries will meet in Dubrovnik to foster international partnership, cooperation and dialogue and discuss the most recent challenges of these industries for the future. With this year’s conference in Croatia, Medicines for Europe and the International Generic and Biosimilar Medicines Association (IGBA) celebrate their first joint event.
Brussels, June 3, 2016 – IGBA thanks the Agency’s for providing an opportunity to comment on the Agency’s Draft Guidance on Labeling for Biosimilar Products (Docket No. FDA-2016-D-0643-0001). IGBA’s position is aligned with the key comments of the Biosimilar Medicines Group, a sector group of Medicines for Europe, which have been submitted separately.
Friday May 27, 2016 – The International Generic and Biosimilar Medicines Association (IGBA) represents companies that are actively engaged in the global manufacturing and trading systems for medicines. Our membership includes the EGA (Europe), the CGPA (Canada), the GPhA (USA), the JAPM (Jordan), the NAPM (South Africa), the TGPA (Taiwan) and the JGA (Japan). Associations from Australia (GBMA), Brazil (ProGenericos), Mexico (AMEGI) and Malaysia (MOPI) are Associate Members.
- IGBA calls for full transparency and new timelines for impact assessment with regard to the voluntary WHO biological qualifier (BQ) proposal
- IGBA Files Recommendations for USTR 2016 Special 301 Review
- Statement by the International Generic and Biosimilar Medicines Association on the Signing of the Trans-Pacific Partnership Agreement
- IGBA letter to FDA regarding their biologics naming proposals